SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

1,995

Sector

Pharmaceuticals

Calendar

04-17 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-03-14	70.65 ¥	+2.42%	4,787,868
25-03-13	68.98 ¥	-1.37%	3,450,033
25-03-12	69.94 ¥	-0.79%	2,626,782
25-03-11	70.50 ¥	+0.66%	3,608,553
25-03-10	70.04 ¥	-0.31%	3,065,699

End-of-day quote Shenzhen S.E., March 13, 2025

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2025-03-14			5-day change	1st Jan Change
70.65 ^CNY	+2.42%		+0.56%	+1.25%

10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
09-22	Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	CI

Capitalization	12.23B 1.69B 1.55B 1.49B 1.31B 2.43B 147B 2.68B 17.14B 6.5B 61.96B 6.33B 6.21B 251B	P/E ratio 2022	51.9x	P/E ratio 2023	94.5x
Enterprise value	11.83B 1.63B 1.5B 1.45B 1.27B 2.35B 142B 2.59B 16.57B 6.28B 59.93B 6.13B 6B 242B	EV / Sales 2022	8.46x	EV / Sales 2023	15.2x
Free-Float	68.04%	Yield 2022	1.2%	Yield 2023	2.03%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	24-09-22	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-28	CI
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	24-07-25	MT
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	24-07-24	MT
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	24-05-21	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	24-04-26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	24-03-13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	24-01-08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	23-12-12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	23-12-12	CI

1 day	+2.42%
1 week	+0.56%
Current month	-0.77%
1 month	-4.60%
3 months	-16.06%
6 months	-1.71%
Current year	+1.25%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Stock

Equities

300573

CNE100002DV1

Pharmaceuticals

Valuation: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Chart: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Latest news: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Press Releases: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Manager	Title	Age	Since
E Gao CEO	Chief Executive Officer	51	2022-07-17
Ya Nan Cheng DFI	Director of Finance/CFO	51	2011-11-11
Chun Hua Li ADM	Chief Administrative Officer	48	2022-02-15

Director	Title	Age	Since
Xiao Yan Kong BRD	Director/Board Member	52	2024-01-04
Ji Dong Liu CHM	Chairman	68	2000-07-04
E Gao BRD	Director/Board Member	51	2011-11-11

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.42%	+0.56%	-49.79%	+46.75%	1.71B
MERCK KGAA	+0.04%	-0.77%	-15.86%	-25.14%	63.59B
KYOWA KIRIN CO., LTD.	-0.05%	-2.00%	-22.50%	-22.41%	7.69B
HALOZYME THERAPEUTICS, INC.	+1.98%	+2.12%	+52.66%	+80.13%	7.67B
YUHAN CORPORATION	+3.65%	+4.96%	+65.96%	+138.46%	6.43B
SK BIOPHARMACEUTICALS CO., LTD.	+1.43%	-0.28%	+11.04%	+20.72%	5.75B
BETTA PHARMACEUTICALS CO., LTD.	+1.72%	-6.56%	+7.05%	-9.64%	2.91B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+1.67%	+3.12%	+29.24%	+17.92%	2.15B
SUPERNUS PHARMACEUTICALS, INC.	+0.29%	-2.53%	-6.32%	+3.82%	1.74B
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
Average	+1.32%	+0.13%	+7.94%	+27.85%	10.13B
Weighted average by Cap.	+0.61%	-0.31%	-3.04%	-0.50%

	2022	2023
Net sales	1.25B 173M 159M 153M 134M 249M 15.01B 273M 1.75B 664M 6.33B 647M 634M 25.61B	1.47B 203M 186M 179M 157M 292M 17.63B 321M 2.06B 779M 7.44B 760M 745M 30.07B
Net income	212M 29.25M 26.88M 25.88M 22.64M 42.1M 2.54B 46.31M 297M 112M 1.07B 110M 107M 4.34B	240M 33.16M 30.48M 29.34M 25.68M 47.74M 2.88B 52.51M 336M 127M 1.22B 124M 122M 4.92B
Net Debt	-502M -69.31M -63.71M -61.32M -53.66M -99.77M -6.03B -110M -703M -266M -2.54B -260M -255M -10.28B	-401M -55.44M -50.96M -49.05M -42.92M -79.8M -4.82B -87.79M -562M -213M -2.03B -208M -204M -8.22B